Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
In the Literature
In the Literature
Pembrolizumab Shows Long-Term Benefits in Metastatic Colorectal Cancer and MSI-H or dMMR
Read More
Graft-versus-Host Disease
,
In the Literature
Sitagliptin, DPP-4 Inhibitor, Reduces the Incidence of Acute GVHD After Stem-Cell Transplant
Read More
In the Literature
Luspatercept Effective in Patients with Lower-Risk Myelodysplastic Syndromes
Read More
In the Literature
Split-Fill Program for Oncology Oral Medications Is Cost-Saving
Read More
In the Literature
Real-World Evidence Supports Patient Navigation in Cancer
Read More
In the Literature
Luspatercept Effective in Patients with Lower-Risk Myelodysplastic Syndromes
Read More
In the Literature
Long-Term Outcomes Affect Cost-Effectiveness of CAR T-Cell Therapy for DLBCL
Read More
In the Literature
Alpelisib Prolongs Progression-Free Survival in Advanced Breast Cancer with PIK3CA Mutation
Read More
In the Literature
New Triple-Drug Regimen for Newly Diagnosed Patients with Multiple Myeloma
Read More
In the Literature
Ibrutinib Superior to Standard Chemoimmunotherapy in Older Patients with CLL
Read More
1
2
Page 1 of 2
Results 1 - 10 of 13